BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2015 and provided a corporate update. The company recently initiated a pivotal Phase 3 trial, PALISADE, of its lead product candidate, AR101 for the treatment of peanut allergy.
